Dicerna Pharmaceuticals said this week that the US Patent and Trademark Office has issued the company a notice of allowance for a patent application covering its core Dicer-substrate technology.
Dicerna did not provide specific details about the intellectual property, but said that the new allowance “applies to 148 claims and provides exclusivity around both in vivo therapeutic and in vitro uses of Dicer-substrates for reducing mammalian target gene expression, regardless of their specific sequence.”
Developed by researchers at the City of Hope and Integrated DNA Technologies, Dicer-substrates are essentially synthetic RNA duplexes around 27 nucleotides long. In animal studies, they have been shown to be more potent than standard 21-mer siRNAs while avoiding immune stimulation.
Dicerna was founded in 2007 to develop the technology for therapeutic applications (GSN 11/8/2007).